Filtered By:
Drug: Empagliflozin

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 127 results found since Jan 2013.

Sitagliptin and other 'gliptins'- why prescribe them?
Authors: Doggrell SA, Dimmitt SB Abstract INTRODUCTION: In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors ('gliptins'). At present, there is contradictory evidence on whether the gliptins increase hospitalizations for heart failure. Areas covered: This is an evaluation of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in high risk cardiovascular subjects with type 2 diabetes [1]. TECOS demonstrated non-inferiority for sitagliptin over placebo for the primary ...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension
Purpose of review: The majority of patients with type 2 diabetes mellitus (T2DM) have hypertension requiring combination therapy. Sodium glucose cotransporter 2 (SGLT2) inhibitors are novel glucose-lowering drugs with shared and potentially unique beneficial effects on cardiovascular risk beyond glycemic control. This review focuses on the potential role of SGLT2 inhibitors in the treatment of hypertension associated with T2DM. Recent findings: SGLT2 inhibitors reduce office SBP by 3–5 mmHg and DBP by 2–3 mmHg across all class members. Corresponding clinically meaningful, significant blood pressure (BP) lowering e...
Source: Current Opinion in Nephrology and Hypertension - February 5, 2016 Category: Urology & Nephrology Tags: PATHOPHYSIOLOGY OF HYPERTENSION: Edited by Nancy J. Brown Source Type: research

Superiority trials: statistical trickery or mass blindness?
Non-inferiority trials are conducted to demonstrate whether a new treatment is not inferior to an existing treatment by more than a prespecified margin, known as the non-inferiority margin (). is thus a critical element in these studies and must be justifiable both statistically and clinically.1 We have recently argued that there should be a superiority margin similar to the non-inferiority margin in superiority trials.2 The current practice is that if 95% CI lies within the inferiority margin () of the no-difference line, the drug is considered to be non-inferior. The drug is considered inferior only if the 95% CI lie out...
Source: Postgraduate Medical Journal - January 25, 2016 Category: Journals (General) Authors: Shafiq, N., Malhotra, S. Tags: Letter Source Type: research

Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Authors: Dailey GE Abstract Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by decreasing renal glucose reabsorption and promoting urinary glucose excretion. In clinical trials, empagliflozin demonstrated significant improvements in glycemic control, as monotherapy and in combination regimens. In addition, empagliflozin was associated with weight loss and moderate reductions in blood pressure. In the EMPA-REG OUTCOME study, empagliflozin significantly reduced the risk of the composite primary endpoint of cardiovascular death, no...
Source: Drugs of Today - October 23, 2015 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research

The EMPA-REG Study: What has it told us? A Diabetologist’s Perspective
EMPA-REG (1) is the first study to conclusively demonstrate that a medication developed to reduce glycemia (2) in patients with type 2 diabetes mellitus (T2DM) decreases cardiovascular events. In 7020 T2DM patients with established cardiovascular (CV) disease, empagliflozin (pooled 10 and 25 mg/day doses) significantly reduced the primary MACE outcome (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% compared to placebo (HR = 0.86, 95% CI = 0.74-0.99, P=0.04 for superiority). It is noteworthy that a striking disconnect was observed between the three MACE components; (i) for nonfatal MI, the HR (=0.87) decreased s...
Source: Journal of Diabetes and Its Complications - October 21, 2015 Category: Endocrinology Authors: Ralph A. DeFronzo Source Type: research

Lilly diabetes drug slashes deaths in patients with heart risk
(Reuters) - Eli Lilly and Co's new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke, a finding that could make it a mainstay diabetes treatment and triple its use, according to researchers and analysts.
Source: Reuters: Health - September 17, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Jardiance, a Diabetes Drug, Cut Cardiovascular Deaths by 38%, Study Says
In a clinical trial, the drug reduced the risk of having a heart attack or stroke, or of dying from cardiovascular causes by 14 percent.
Source: NYT Health - September 17, 2015 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Johnson & Johnson JNJ NYSE Heart Drugs (Pharmaceuticals) Eli Lilly and Company LLY NYSE Stroke Merck Company Inc MRK NYSE Diabetes Boehringer Ingelheim GmbH Source Type: news